

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 February 2021 (04.02.2021)



(10) International Publication Number
WO 2021/021909 A1

(51) International Patent Classification:

A61K 31/343 (2006.01) A61K 9/20 (2006.01)
C07D 307/80 (2006.01) A61K 9/48 (2006.01)
C07D 405/10 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2020/044037

(22) International Filing Date:

29 July 2020 (29.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/881,225	31 July 2019 (31.07.2019)	US
62/926,175	25 October 2019 (25.10.2019)	US
63/020,239	05 May 2020 (05.05.2020)	US

(71) Applicant: **BIOCRYST PHARMACEUTICALS, INC.**

[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).

(72) Inventors: **BABU, Yarlalagadda, S.**; 4836 Southlake Parkway, Birmingham, AL 35244 (US). **SHERIDAN, William, P.**; 4505 Emperor Blvd., Suite 200, Durham, NC 27703 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DOSING REGIMENS FOR ORAL COMPLEMENT FACTOR D INHIBITORS

(57) Abstract: Disclosed are compounds and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are oral dosage forms comprising such a compound, salt, or prodrug. Also disclosed are methods of using the compounds, salts, and prodrugs, and oral dosage forms thereof, in the treatment or prevention of a disease or condition characterized by aberrant complement system activity (e.g., paroxysmal nocturnal hemoglobinuria).



WO 2021/021909 A1